Among patients who had prior ROS1 inhibitor treatment, 38 percent responded to Augtyro. CHMP's recommendation for Augtyro in adult and pediatric patients 12 years of age and older with advanced solid ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India We selected 250 consecutive participants from the SECOC ...

Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

The Princeton, N.J., biopharmaceutical company said the recommendation cover Augtyro as a treatment for adults with ROS1-positive advanced ... expressing a NTRK gene fusion. The European ...